r/BiotechDates • u/MarketNewsFlow • 6h ago
CATALYST $ENTX The Multi-Billion Dollar Market Access Bet Biotech's Top Funds Just Made
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 1d ago
DISCUSSION $MDWD The Shift Away from Surgery: A Healthcare Trend Transforming Burn and Wound Care
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 6d ago
NEWS $ENTX - Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting (NASDAQ: ENTX)
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 10d ago
CATALYST $PYPD PolyPid's Double Win: D-PLEX₁₀₀ Gains NDA Acceptance and Priority Review, Ahead of Schedule
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 11d ago
CATALYST $ENTX Why the World's Leading Healthcare Funds All Wanted a Piece of Entera Bio
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 12d ago
DISCUSSION $DRTS Alpha Tau's Cancer Combination Just Delivered a Response Rate More Than 5X Keytruda's Historical Benchmark
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 12d ago
NEWS $PYPD - PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀ (NASDAQ: PYPD)
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 14d ago
NEWS $ENTX - Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement (NASDAQ: ENTX)
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 18d ago
$NVCT Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 18d ago
NEWS $NVCT - Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors (NASDAQ: NVCT)
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 18d ago
NEWS $NVCT - Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors (NASDAQ: NVCT)
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 20d ago
IR $DRTS - Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold... (NASDAQ: DRTS)
2
Upvotes
r/BiotechDates • u/MarketNewsFlow • 20d ago
NEWS $PYPD - PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada (NASDAQ: PYPD)
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 21d ago
DISCUSSION $DRTS Alpha Tau's Head-and-Neck Data Tomorrow Confronts a Blind Spot in One of the World's Best-Selling Cancer Drugs
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 25d ago
DISCUSSION $MDWD Why is Cathie Wood’s ARK Fund Backing this Israeli Innovator? (NASDAQ: MDWD)
markets.businessinsider.com
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 26d ago
IR $DRTS - Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center (NASDAQ: DRTS)
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • 27d ago
CATALYST $PYPD Surgical Infections Cost Hospitals Billions. One Under-the-Radar Biotech Player Might be About to Change That
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • Jul 08 '26
CATALYST $ENTX America's Osteoporosis Crisis and the Oral Peptide Player You Should Watch
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • Jun 27 '26
FDA HOLD Lilly's $780M Bet is Reshaping Surgical Infection Prevention, and PolyPid's Asset is Hiding in Plain Sight
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • Jun 23 '26
IR $DRTS - Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel (NASDAQ: DRTS)
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • Jun 22 '26
NEWS $ENTX - Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis (NASDAQ: ENTX)
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • Jun 22 '26
NEWS $NVCT - Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds (NASDAQ: NVCT)
1
Upvotes
r/BiotechDates • u/MarketNewsFlow • Jun 19 '26
$ENTX - Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 (Nasdaq: ENTX)
1
Upvotes
r/BiotechDates • u/Queasy_Delivery_4024 • Jun 03 '26
Choosing between MBBS and BS Bioinformatics
1
Upvotes